Biocon FY26 results: ₹16,927 Cr revenue, 10% dividend

Board meeting: what Biocon approved on May 7

Biocon Ltd. said its board met on May 7, 2026, to approve the audited financial results for the year ended March 31, 2026. Alongside the results, the board recommended a final dividend for FY26 and cleared a capital-structure step linked to Biocon Biologics Limited (BBL). The company also announced a change in statutory auditors for a five-year term and a set of board and senior management designations. Biocon additionally scheduled its next Annual General Meeting (AGM) and rolled out a new long-term incentive plan. The actions together point to two priorities: closing FY26 compliance and moving BBL towards full integration. These decisions were disclosed through regulatory filings on the exchanges.

FY26 financial performance: revenue and profit numbers cited

For FY26, Biocon reported consolidated revenue of ₹16,927.0 crore (₹1,69,270 million). The same material also referenced the previous year’s consolidated revenue as ₹15,261.7 crore (₹1,52,617 million). On profit, one section stated consolidated net profit of ₹1,429.4 crore (₹14,294 million) for the year. Another section in the provided disclosures mentioned consolidated net profit of ₹368.8 crore (₹3,688 million) for FY26, creating an inconsistency within the shared text. On a standalone basis, the company reported revenue of ₹2,346.4 crore (₹23,464 million) and net profit of ₹37.2 crore (₹372 million) for the year. Because the figures appear in different parts of the same compiled disclosure text, investors typically rely on the audited statements and accompanying notes for the definitive line items.

Dividend recommendation: 10% final dividend and key dates

The board recommended a final dividend of 10%, which works out to ₹0.50 per equity share. The face value cited for the equity share is ₹5. The dividend remains subject to shareholder approval at the AGM. Biocon disclosed July 3, 2026, as the record date to determine shareholder eligibility. The company also indicated the dividend payout would be made on or before August 31, 2026, if approved. These dates matter for investors tracking entitlement and expected timelines for cash flows.

BBL stake purchase: up to ₹330.73 crore for around 2%

A key strategic decision was the approval to acquire approximately 2% of Biocon Biologics Limited (BBL) equity for up to ₹330.73 crore. The transaction is proposed via a preferential issue or special issuance of Biocon shares, as described in the disclosures. The stated objective is to integrate BBL and make it a wholly owned subsidiary. In the same material, Biocon also described the broader integration as a share swap mechanism intended to create a unified global biopharmaceutical structure, while keeping BBL as the operational biosimilar platform. The company flagged that completion of the BBL acquisition is targeted for June 30, 2026. It also noted that delays in securing approvals could impact the integration timeline.

Preferential issue details: shares and pricing disclosed

Biocon disclosed that the preferential issue could involve issuing up to 87,92,317 equity shares. The issue price cited is ₹376.16 per share. The share issuance is positioned as consideration for acquiring remaining BBL shares held by employees and other shareholders, aligning with the stated goal of full ownership. The company’s earlier disclosures also described that the remaining BBL shares include holdings linked to employee stock options and other minority holders. Any preferential issuance typically requires a defined process under applicable regulations and approvals, which the company referenced as a dependency for timelines. The numbers provided indicate a structured route to settle acquisition consideration through equity rather than only cash.

Auditor change: S. R. Batliboi & Associates LLP appointed

Biocon said the board recommended M/s S. R. Batliboi & Associates LLP as statutory auditors for a five-year term. The term described in the filing spans 2026 to 2031. The new auditor appointment is set to succeed the previous auditors. Such changes are commonly placed before shareholders for approval, and are also disclosed as part of governance updates around annual results. For investors, the disclosure is primarily a compliance and governance signal rather than an operating event, but it remains an important statutory appointment.

Board and leadership updates: independent directors and SMP designations

The company disclosed multiple board appointments, including five Independent Directors: Rajiv Malik, Daniel Bradbury, Peter Baron Piot, Arun Suresh Chandavarkar, and Nivruti Rai. Their appointment was stated as effective August 1, 2026, in the provided text. The disclosures also referred to the appointment of one Non-Executive Director, without naming the individual in the shared extract. Separately, Biocon designated Dr. Anuj Goel (Chief Development Officer) and Susheel Umesh (Chief Commercial Officer – Emerging Markets) as Senior Management Personnel. These moves were described as strengthening the leadership structure as Biocon works through strategic integration steps and routine governance actions.

Incentives, AGM schedule, and investor call

Biocon said the board approved the “Biocon Unity Long Term Incentive Plan 2026,” covering stock-based incentives and employee purchase plans for eligible employees across the company and subsidiaries. The company scheduled its 48th AGM for August 6, 2026. On the communication front, Biocon also scheduled an earnings conference call for May 8, 2026 at 09:00 IST via Zoom, with recordings and transcripts to be made available within specified timelines. The filings also mentioned a trading window closure from April 1 to May 9, 2026, and reopening on May 10, 2026, aligning with insider trading compliance norms around results.

Key numbers and dates at a glance

Why the announcements matter for investors

The dividend recommendation sets a clear FY26 shareholder payout proposal, with record date and payout timeline disclosed upfront. The BBL transaction is more structural, because it is linked to bringing the biologics subsidiary under full ownership through a defined issuance and share swap route. The size and pricing of the preferential issue, along with the cap of ₹330.73 crore for buying about 2%, indicate that the remaining minority stake is being addressed through a planned, disclosed mechanism. Governance changes such as auditor appointment and board refresh are also material to disclosure standards, particularly in a year when the company is executing integration steps. Near-term milestones are explicit in the text: AGM approval for dividend and corporate actions, and the June 30, 2026 target for the BBL stake completion subject to approvals.

Conclusion

Biocon’s FY26 board outcomes combined audited results, a proposed 10% final dividend, and a defined step to acquire about 2% more in BBL for up to ₹330.73 crore. The company also disclosed an auditor change, new board appointments effective August 1, 2026, and an employee long-term incentive plan. Investors will watch the May 8 earnings call for management commentary and the August 6 AGM for shareholder approvals, while the BBL integration timeline remains linked to regulatory and shareholder clearances.